Displaying drugs 11276 - 11300 of 11783 in total
BJ-001
BJ-001 is a recombinant human interleukin-15/IL-15 receptor alpha complex with linked integrin-binding motif.
Investigational
Matched Description: … BJ-001 is a recombinant human interleukin-15/IL-15 receptor alpha complex with linked integrin-binding …
MBX-2109
MBX-2109 is a long-acting parathyroid hormone peptide prodrug under investigation for the treatment of hyperparathyroidism.
Investigational
Matched Description: … MBX-2109 is a long-acting parathyroid hormone peptide prodrug under investigation for the treatment of …
Zigakibart
Zigakibart is under investigation in clinical trial NCT05852938 (A Study of BION-1301 in Adults With Iga Nephropathy).
Investigational
Matched Description: … Zigakibart is under investigation in clinical trial NCT05852938 (A Study of BION-1301 in Adults With …
Ifenprodil
N-methyl-D-aspartate (NMDA) receptors (NMDARs) are members of the ionotropic glutamate receptor family, with key roles in brain development and neurological function.[A220118, A220128] NMDARs are heterotetramers that typically involve a dimer of dimers of both GluN1 and GluN2A-D subunits, with each subunit itself composed of an N-terminal domain (NTD), a ligand-binding...
Investigational
Withdrawn
Matched Description: … domain (LBD), a transmembrane domain, and a C-terminal cytoplasmic domain. ... [A220118, A220128] NMDARs are heterotetramers that typically involve a dimer of dimers of both GluN1 ... and GluN2A-D subunits, with each subunit itself composed of an N-terminal domain (NTD), a ligand-binding …
Tosedostat
Tosedostat has been used in trials studying the treatment and supportive care of AML, Leukemia, Pancreas Cancer, Multiple Myeloma, and Pancreatic Cancer, among others.
Tosedostat is an inhibitor of the M1 family of aminopeptidases, in particular PuSA, and LTA4 hydrolase. It has demonstrated anti-tumour activity in a number of models...
Investigational
Matched Description: … It has demonstrated anti-tumour activity in a number of models of cancer, both as a single agent and …
Hyperforin
Hyperforin is a phytochemical generated by the plants of the Hypericum family. One of the most important members of this family, due to its medical properties, is Hypericum perforatum, also known as St John's wort.
Nutraceutical
Matched Description: … Hyperforin is a phytochemical generated by the plants of the Hypericum family. …
IR501
IR501 (Ravax) is a potential first-in-class vaccine for the treatment of Rheumatoid Arthritis. It specifically targets autoreactive T-cells, reducing their activity. It was last known to be in phase III clinical trials.
Investigational
Matched Description: … IR501 (Ravax) is a potential first-in-class vaccine for the treatment of Rheumatoid Arthritis. …
Ravagalimab
Ravagalimab is under investigation in clinical trial NCT03695185 (A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe It Is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy).
Investigational
Matched Description: … Ravagalimab is under investigation in clinical trial NCT03695185 (A Study to Investigate How Well Ravagalimab …
Tulisokibart
PRA023 is a humanized monoclonal antibody directed to vascular endothelial growth inhibitor, also known as tumour necrosis factor (TNF)-like ligand 1A (TL1A) and TNF superfamily member 15. It is being investigated for ulcerative colitis.
Investigational
Matched Description: … PRA023 is a humanized monoclonal antibody directed to vascular endothelial growth inhibitor, also known …
Vepdegestrant
Vepdegestrant is under investigation in clinical trial NCT05909397 (A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer).
Investigational
Matched Description: … Vepdegestrant is under investigation in clinical trial NCT05909397 (A Study of ARV-471 (PF-07850327) …
Mitiglinide
Mitiglinide is a drug for the treatment of type 2 diabetes. It may stimulate insulin secretion in beta-cells by closing off ATP dependant potassium ion channels.
Investigational
Matched Description: … Mitiglinide is a drug for the treatment of type 2 diabetes. …
NGX267
NGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.
Investigational
Matched Description: … NGX267 is a muscarinic agonist. …
PF-06282999
Pf 06282999 is under investigation in clinical trial NCT01626976 (A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects).
Investigational
Matched Description: … Pf 06282999 is under investigation in clinical trial NCT01626976 (A Study To Assess The Safety, Tolerability …
JNJ-42396302
Jnj 42396302 is under investigation in clinical trial NCT01732237 (A Study to Investigate the Pharmacokinetics of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male Participants).
Investigational
Matched Description: … Jnj 42396302 is under investigation in clinical trial NCT01732237 (A Study to Investigate the Pharmacokinetics …
Reposal
Reposal is a barbiturate derivative invented in the 1960s in Denmark that has sedative, hypnotic and anticonvulsant properties. It was used primarily in the treatment of insomnia.
Experimental
Matched Description: … Reposal is a barbiturate derivative invented in the 1960s in Denmark that has sedative, hypnotic and …
Elenbecestat
Elenbecestat is under investigation in clinical trial NCT02956486 (A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease).
Investigational
Matched Description: … Elenbecestat is under investigation in clinical trial NCT02956486 (A 24-Month Study to Evaluate the Efficacy …
Giripladib
Giripladib is under investigation in clinical trial NCT00396955 (A Study Comparing 4 Dose Regimens of PLA-695, Naproxen, and Placebo In Subjects With Osteoarthritis Of The Knee).
Investigational
Matched Description: … Giripladib is under investigation in clinical trial NCT00396955 (A Study Comparing 4 Dose Regimens of …
CYNK-001
CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.
Investigational
Matched Description: … CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental …
Birtamimab
Birtamimab is under investigation in clinical trial NCT02312206 (The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis).
Investigational
Matched Description: … Birtamimab is under investigation in clinical trial NCT02312206 (The VITAL Amyloidosis Study, a Global …
IO-202
IO-202 is a first-in-class antibody targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) member 4 (LILRB4). It is being investigated in cancers.
Investigational
Matched Description: … IO-202 is a first-in-class antibody targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B …
Reloxiliase
Reloxiliase is a first-in-class, oral crystalline formulation of the oxalate-specific, microbial enzyme oxalate decarboxylase. It is being investigated for the treatment of hyperoxaluria.
Investigational
Matched Description: … Reloxiliase is a first-in-class, oral crystalline formulation of the oxalate-specific, microbial enzyme …
Rhamnose
A methylpentose whose L- isomer is found naturally in many plant glycosides and some gram-negative bacterial lipopolysaccharides. [PubChem]
Experimental
Matched Description: … A methylpentose whose L- isomer is found naturally in many plant glycosides and some gram-negative bacterial …
V24343
The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.
Investigational
Matched Description: … The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's …
MBT-0312
MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.
Investigational
Matched Description: … MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving …
Denibulin
Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor cancers.
Investigational
Matched Description: … Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment …
Displaying drugs 11276 - 11300 of 11783 in total